CytoDyn to Hold Webcast to Provide a Quarterly Company Update
CytoDyn Inc. (OTCQB: CYDY) announced an investment community webcast scheduled for September 28, 2022, at 1:00 pm PT / 4:00 pm ET. The event will feature Board Chair Tanya Urbach, President Cyrus Arman, CFO Antonio Migliarese, and CMO Scott Kelly, who will provide a quarterly update on the company's developments, particularly regarding leronlimab, a CCR5 antagonist. Questions for the webcast can be submitted until Noon PT on September 26, 2022. A replay will be available after the event until October 28, 2022.
- Scheduled quarterly update webcast indicates transparency and engagement with investors.
- Leadership presence may boost investor confidence and interest in leronlimab developments.
- Timing of the event might coincide with investor skepticism if recent results were unsatisfactory.
VANCOUVER, Washington, Sept. 19, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Tanya Urbach, Board Chair, Cyrus Arman, President, Antonio Migliarese, Chief Financial Officer, and Scott Kelly, Chief Medical Officer and Head of Business Development, will host an investment community webcast to provide a quarterly Company update on Wednesday, September 28, 2022.
Following the update, questions submitted prior to the webcast as directed below will be addressed to the extent appropriate.
Date: | Wednesday, September 28, 2022 |
Time: | 1:00 pm PT / 4:00 pm ET |
Access: | https://event.choruscall.com/mediaframe/webcast.html?webcastid=dfBGdCbQ |
Questions: | Submit questions prior to the webcast to ir@cytodyn.com not later than Noon PT, Monday, September 26, 2022 |
This is a livestream presentation. Participants are encouraged to login early prior to the start of the event. The replay will be available approximately 60 minutes after the conclusion of the webcast and can be accessed via the above link until October 28, 2022.
CONTACTS
Investors:
Cristina De Leon
Office: 360.980.8524
ir@cytodyn.com
Media:
Dan Zacchei / Joe Germani
Longacre Square Partners
dzacchei@longacresquare.com / jgermani@longacresquare.com
FAQ
When is the CytoDyn investment community webcast?
Who will present at the CytoDyn webcast?
How can I submit questions for the CytoDyn webcast?